國家衛生研究院 NHRI:Item 3990099045/4386
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 859586      線上人數 : 681
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版
    國家衛生研究院 NHRI > 癌症研究所 > 其他 > 期刊論文 >  Item 3990099045/4386


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4386


    題名: Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
    作者: Hsu, C;Kuo, SH;Hu, FC;Cheng, AL;Shih, JY;Yu, CJ;Lin, CC;Huang, TC;Yang, PC;Yang, CH
    貢獻者: National Institute of Cancer Research
    摘要: Background: Epirubicin was effective for the treatment of non-small cell lung carcinoma (NSCLC). This study compared the efficacy and safety of gemcitabine plus conventional-dose epirubicin (GE) with gemcitabine-cisplatin (GC) as first-line chemotherapy for stage IIIB/IV NSCLC and evaluated the predictive value of nuclear expression of excision repair cross-complementing group 1 (ERCC1) and topoisomerase II alpha (Topolla) on treatment outcome. Patients and methods: Patients were randomized to GE (gemcitabine, 1000 mg/m(2) on days 1, 8, and 15 and epirubicin, 70 mg/m(2) on day 15) or GC (gemcitabine, 1000 mg/m(2) on days 1, 8, and 15 and cisptatin, 80 mg/m(2) on day 15). Treatment cycles were repeated every 4 weeks. Immunohistochemical study of ERCC1 and TopoII alpha was done for patients with available tumor specimens. Results: The response rate was 31.0% (95% CI 16.4-45.5%) for GC (n = 41) and 37.2.0% (95% CI 22.2-52.3%) for GE (n = 39). No significant differences in median time-to-treatment-failure (TTF) (GC, 6.1 months; GE, 6.2 months) or overall survival (GC, 13.2 months; GE, 21.5 months) were found between the two arms. Grade 3/4 neutropenia and febrile neutropenia were more common in GE. However, delay of protocol treatment due to leukopenia was similar between the two arms. Patients with expression of both ERCC1 and TopoII alpha had a significantly shorter TTF (median 2.4 months, 95% CI 0.7-4.1 months) than other patients (median 8.8 months, 95% CI 5.8-11.8 months) (p=0.04). Conclusion: GE regimen is effective and well-tolerated for NSCLC patients. Expression of both ERCC1 and TopoII alpha may be associated with poor response to chemotherapy.
    日期: 2008-12
    關聯: Lung Cancer. 2008 Dec;62(3):334-343.
    Link to: http://dx.doi.org/10.1016/j.lungcan.2008.03.010
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0169-5002&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000262217700009
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=45849137388
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000262217700009.pdf505KbAdobe PDF591檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋